Personalized Posaconazole Treatment and Monitoring Systems

The present invention relates to improved methods and systems for treating and preventing invasive fungal infections in immunocompromised patients, particularly those undergoing hematopoietic stem cell transplantation or chemotherapy. The inventive concept addresses the limitations of current posaconazole treatment regimens by providing personalized dosage and treatment monitoring systems, enhancing efficacy and reducing side effects.

The original patent disclosed methods of treatment using posaconazole, but had limitations in terms of dosage and treatment monitoring. The new inventive concept addresses these limitations by providing systems and methods for personalized treatment, reducing the risk of invasive fungal infections and improving patient outcomes.

The inventive concept comprises a system for personalized treatment of hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy. The system includes a database of patient characteristics and a predictive model for determining optimal posaconazole dosage. Additionally, the inventive concept includes methods for reducing the risk of invasive Aspergillus and Candida infections in immunocompromised patients by administering posaconazole in combination with a CYP3A4 inhibitor to increase bioavailability. Furthermore, the inventive concept encompasses pharmaceutical compositions and systems for monitoring and adjusting posaconazole treatment in patients with hematologic malignancies.

The new inventive concept is novel and non-obvious in its provision of personalized treatment and monitoring systems, which overcome the limitations of current posaconazole treatment regimens. The use of predictive models, biomarker detection, and treatment adjustment algorithms provides a significant improvement over existing methods.

Alternative embodiments of the inventive concept could include the use of machine learning algorithms to predict optimal posaconazole dosage, or the integration of the system with electronic health records to facilitate seamless data exchange. Variations could also include the use of different predictive models or biomarkers to determine optimal treatment regimens.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of hematopoietic stem cell transplantation and chemotherapy. The market for personalized medicine and treatment monitoring systems is growing rapidly, and the inventive concept is well-positioned to capitalize on this trend.